Last reviewed · How we verify
Hôpital le Vinatier — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
1 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Cannabidiol oral oil | Cannabidiol oral oil | marketed | Cannabinoid | Multiple (5-HT1A, TRPV1, CB1, CB2, glycine receptors) | Neurology/Psychiatry | |
| Placebo oral oil | Placebo oral oil | phase 3 |
Therapeutic area mix
- Neurology/Psychiatry · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Gold Coast Hospital and Health Service · 1 shared drug class
- Montefiore Medical Center · 1 shared drug class
- OMNI Medical Services, LLC · 1 shared drug class
- Staci Gruber, Ph.D. · 1 shared drug class
- Stero Biotechs Ltd. · 1 shared drug class
- University of California, San Diego · 1 shared drug class
- University of Connecticut · 1 shared drug class
- Wayne State University · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Hôpital le Vinatier:
- Hôpital le Vinatier pipeline updates — RSS
- Hôpital le Vinatier pipeline updates — Atom
- Hôpital le Vinatier pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Hôpital le Vinatier — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/h-pital-le-vinatier. Accessed 2026-05-16.